We are live on ! Find out more
FCM

Flinton Capital Management Portfolio holdings

AUM $3.22B
1-Year Est. Return 4.75%
This Fund
S&P 500
This Quarter Est. Return
+14.64%
1 Year Est. Return
+4.75%
3 Year Est. Return
+57.46%
5 Year Est. Return
10 Year Est. Return
AUM
$3.05B
AUM Growth
+$402M
Cap. Flow
+$36.6M
Cap. Flow %
1.2%
Top 10 Hldgs %
28.92%
Holding
900
New
38
Increased
320
Reduced
186
Closed
26

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$15.7M
2
HD icon
Home Depot
HD
+$11.4M
3
CVX icon
Chevron
CVX
+$8.68M
4
AOS icon
A.O. Smith
AOS
+$8.05M
5
MSFT icon
Microsoft
MSFT
+$7.19M

Top Sells

Rank Stock Value
1
BBY icon
Best Buy
BBY
+$12.7M
2
MPC icon
Marathon Petroleum
MPC
+$11.2M
3
DXC icon
DXC Technology
DXC
+$10.6M
4
WBA
Walgreens Boots Alliance
WBA
+$9.22M
5
BA icon
Boeing
BA
+$8.43M

Sector Composition

Rank Sector Weight
1 Technology 23.36%
2 Healthcare 18.04%
3 Industrials 12.67%
4 Financials 12.38%
5 Consumer Discretionary 7.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ENV
851
DELISTED
ENVESTNET, INC.
ENV
$19K ﹤0.01%
288
+16
+6% +$921
ALEC icon
852
Alector
ALEC
$203M
$18K ﹤0.01%
+980
New +$18.5K
CHRS icon
853
Coherus Oncology
CHRS
$194M
$18K ﹤0.01%
1,296
+272
+27% +$3.63K
REPL icon
854
Replimune Group
REPL
$1.08B
$18K ﹤0.01%
1,148
TBPH icon
855
Theravance Biopharma
TBPH
$877M
$17K ﹤0.01%
748
MEOH icon
856
Methanex
MEOH
$4.21B
$16K ﹤0.01%
288
BB icon
857
BlackBerry
BB
$5.15B
$14K ﹤0.01%
1,472
INXN
858
DELISTED
Interxion Holding N.V.
INXN
$14K ﹤0.01%
208
ARRY
859
DELISTED
Array Biopharma Inc
ARRY
$14K ﹤0.01%
592
+400
+208% +$8.33K
IOVA icon
860
Iovance Biotherapeutics
IOVA
$2.77B
$13K ﹤0.01%
1,316
-140
-10% -$1.36K
QTWO icon
861
Q2 Holdings
QTWO
$3.95B
$13K ﹤0.01%
192
KGC icon
862
Kinross Gold
KGC
$30.4B
$12K ﹤0.01%
3,504
BMRN icon
863
BioMarin Pharmaceuticals
BMRN
$11.9B
$11K ﹤0.01%
+128
New +$11.9K
DNLI icon
864
Denali Therapeutics
DNLI
$3.92B
$10K ﹤0.01%
432
TBHC
865
DELISTED
The Brand House Collective
TBHC
$10K ﹤0.01%
1,424
ESLT icon
866
Elbit Systems
ESLT
$40.2B
$9K ﹤0.01%
68
ARNA
867
DELISTED
Arena Pharmaceuticals Inc
ARNA
$9K ﹤0.01%
192
CHMA
868
DELISTED
Chiasma, Inc. Common Stock
CHMA
$7K ﹤0.01%
+1,288
New +$5.67K
ALNA
869
DELISTED
Allena Pharmaceuticals
ALNA
$6K ﹤0.01%
812
-28
-3% -$203
BPY
870
DELISTED
Brookfield Property Partners L.P. Limited Partnership Units
BPY
$6K ﹤0.01%
280
ASMB icon
871
Assembly Biosciences
ASMB
$524M
$5K ﹤0.01%
23
-21
-48% -$5.32K
XBI icon
872
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$3K ﹤0.01%
+34
New +$2.89K
PTE
873
DELISTED
PolarityTE, Inc. Common Stock
PTE
$3K ﹤0.01%
10
XLB icon
874
State Street Materials Select Sector SPDR ETF
XLB
$8.55B
$2K ﹤0.01%
56
AA icon
875
Alcoa
AA
$12.5B
-1,848
Closed -$49K

Similar funds

Flinton Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Flinton Capital Management held 900 positions worth $3.05B, up 15% from $2.64B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Flinton Capital Management's Q1 2019 filing shows 38 new, 320 increased, 186 reduced and 26 closed positions. Its largest new stake was Capri Holdings: 100,520 shares worth $4.6M. The largest sale was Best Buy, an estimated $12.7M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 23% a quarter earlier, followed by Healthcare and Industrials.

  • Flinton Capital Management's largest Q1 2019 buy was Capri Holdings: 100,520 shares worth $4.6M.
  • Flinton Capital Management added most to Merck in Q1 2019, an estimated $15.7M increase.
  • Flinton Capital Management's biggest Q1 2019 reduction was Best Buy, cutting an estimated $12.7M.
  • Flinton Capital Management fully exited SunTrust Banks, Inc. in Q1 2019, selling an estimated $3M.
  • Flinton Capital Management's ten largest holdings make up 29% of its $3.05B portfolio in Q1 2019.
  • Flinton Capital Management opened 38 new positions and closed 26 in Q1 2019.
  • Flinton Capital Management's portfolio value rose 15% quarter-over-quarter to $3.05B.

Based on Flinton Capital Management's 13F filing for Q1 2019, filed 13 May 2019.